Phosphocreatine recovery time constant (PCr) at peak exercise as a potential endpoint for clinical trials in PAD by unknown
POSTER PRESENTATION Open Access
Phosphocreatine recovery time constant (PCr) at
peak exercise as a potential endpoint for clinical
trials in PAD
Jorge A Gonzalez1*, Yan Li1, Peter W Shaw1, Pelbreton Balfour1, Yang Yang3, Jennifer Kay2, Joseph DiMaria2,
Arthur Weltman4, Michael Salerno1,3, Craig H Meyer3, Frederick H Epstein3, Christopher M Kramer1,2
From 19th Annual SCMR Scientific Sessions
Los Angeles, CA, USA. 27-30 January 2016
Background
Patients with PAD who have intermittent claudication
have reduced exercise tolerance, however, the mechan-
isms are not well understood. Ankle-brachial index
(ABI) correlates neither with walking distance nor the
degree of claudication or functional limitation as it is
only able to measure flow at the macrovascular level.
31phosphocreatine (31p) is a non-invasive marker of
mitochondrial capacity in the skeletal muscle providing
an insight into muscle metabolism and tissue perfusion.
We sought to analyze the relationship of 31p recovery
time constant (PCr) and exercise capacity in a popula-
tion with PAD.
Methods
Twenty-three (23) patients with PAD (ABI < 0.9) were
prospectively enrolled. All performed supine plantar
flexion exercise at 50 rpm using a pedal ergometer until
exhaustion or limiting symptoms. PCr was measured by
31p MR spectroscopy using a 3 T Siemens Trio MR
scanner during recovery after peak exercise. A single-
pulse, surface coil localized 512 msec free induction
decay acquisition with 20 averages centered on the mid-
calf was used. A standard 31p surface coil in the patient
table is employed. PCr was then calculated using a
monoexponential fit of phosphocreatine concentration
versus time, beginning at cessation of exercise. Patients
later exercised on a treadmill (Gardner exercise proto-
col) and completed a 6 min-walk protocol. Peak VO2
(peak oxygen consumption) was measured. METS
(Metabolic equivalents), total distance (feet), total
exercise time and start of claudication time were also
recorded.
Results
The mean age was 67 ± 11 years, 63% were male, 63%
were Caucasian, the mean ABI was 0.69 ± 0.09. The
mean logPCr was 1.68 ± 0.25, 6-min walk distance
1024.7 ± 351.9 feet, 6-min walk start of claudication
330.0 ± 274.2 feet, peak VO2 13.4 ± 3.7 (ml/kg/min),
METS 3.8 ± 1.1, treadmill exercise time 5.8 ± 4.4 min.
PCr correlated with 6-min walk total distance (Pearson’s
r: 0.43, p = 0.04), total METS (r = 0.49, p = 0.02) and
peak VO2 (r = 0.49, p = 0.02). No correlation was seen
between PCr and claudication distance (p = 0.27) nor
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Figure 1 PCr calculation based of the monoexponential fit of
phosphocreatine concentration vs time.
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start of leg discomfort (p = 0.24). ABI did not correlate
with any of these exercise parameters.
Conclusions
PCr recovery time constant correlates significantly with
total distance, METS and peak VO2 in patients with
PAD whereas ABI does not. PCr recovery kinetics could
be used a therapeutic target in novel interventions in
patients with PAD as it correlates better with exercise
parameters than ABI.
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